Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Profitability
This table compares Vivos Therapeutics and XORTX Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -127.70% | -2,325.64% | -98.12% |
| XORTX Therapeutics | N/A | -150.01% | -106.53% |
Valuation & Earnings
This table compares Vivos Therapeutics and XORTX Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $19.57 million | 0.44 | -$21.17 million | ($2.14) | -0.29 |
| XORTX Therapeutics | N/A | N/A | -$2.66 million | ($2.63) | -0.81 |
XORTX Therapeutics has lower revenue, but higher earnings than Vivos Therapeutics. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Vivos Therapeutics has a beta of 6.1, indicating that its stock price is 510% more volatile than the S&P 500. Comparatively, XORTX Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
Insider and Institutional Ownership
26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Vivos Therapeutics and XORTX Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| XORTX Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 356.25%. Given Vivos Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Vivos Therapeutics is more favorable than XORTX Therapeutics.
Summary
Vivos Therapeutics beats XORTX Therapeutics on 9 of the 13 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
About XORTX Therapeutics
Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
